1. Generics Bulletin
  2. >>Products

Glenmark Expects ‘Strong Year’ With ‘First’ EU Spiriva Rival Imminent

Signed Licensing Deal For Tiotropium Bromide In 2018

 
• By Dean Rudge

Glenmark said it would continue to deliver new respiratory products in Europe moving forward as the Indian firm lines up what it believes will be the first generic version of Boehringer Ingelheim’s Spiriva Handihaler.

Rocket
Glenmark is anticipating a first launch in Europe • Source: Shutterstock

Glenmark Pharmaceuticals says it “expects to be one of the first generics” for a generic version of Boehringer Ingelheim’s Spiriva Handihaler (tiotropium bromide) dry-powder inhaler, and “should be launching anytime soon.”

The Indian firm, which continues to take steps to build its global respiratory franchise, in-licensed the product more than three years ago, after its success in Europe with Polish firm Celon Pharma covering a generic of GlaxoSmithKline’s (GSK’s) Seretide Accuhaler (fluticasone/salmeterol) dry-powder inhaler

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By Dean Rudge

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.